Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Clinical significance of Pseudomonas aeruginosa 2-alkyl-4-quinolone quorum-sensing signal molecules for long-term outcomes in adults with cystic fibrosis.

Webb K, Fogarty A, Barrett DA, Nash EF, Whitehouse JL, Smyth AR, Stewart I, Knox A, Williams P, Halliday N, Cámara M, Barr HL.

J Med Microbiol. 2019 Oct 31. doi: 10.1099/jmm.0.001099. [Epub ahead of print]

PMID:
31671047
2.

Pro Con Debate - Infection prevention and control in cystic fibrosis: One size fits all The argument against.

Smyth AR, Smith SJ, Rowbotham NJ.

Paediatr Respir Rev. 2019 Aug 21. pii: S1526-0542(19)30066-1. doi: 10.1016/j.prrv.2019.08.001. [Epub ahead of print] Review.

PMID:
31629644
3.

Rojiroti microfinance and child nutrition: a cluster randomised trial.

Ojha S, Szatkowski L, Sinha R, Yaron G, Fogarty A, Allen SJ, Choudhary S, Smyth AR.

Arch Dis Child. 2019 Oct 10. pii: archdischild-2018-316471. doi: 10.1136/archdischild-2018-316471. [Epub ahead of print]

4.

Using digital technology for home monitoring, adherence and self-management in cystic fibrosis: a state-of-the-art review.

Calthorpe RJ, Smith S, Gathercole K, Smyth AR.

Thorax. 2019 Oct 8. pii: thoraxjnl-2019-213233. doi: 10.1136/thoraxjnl-2019-213233. [Epub ahead of print]

PMID:
31594802
5.

Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.

Bhatt J, Jahnke N, Smyth AR.

Cochrane Database Syst Rev. 2019 Sep 4;9:CD002009. doi: 10.1002/14651858.CD002009.pub7.

PMID:
31483853
6.

Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis.

Rowbotham NJ, Smith SJ, Elliott ZC, Leighton PA, Rayner OC, Morley R, Smyth AR.

Res Involv Engagem. 2019 Aug 20;5:24. doi: 10.1186/s40900-019-0159-x. eCollection 2019.

7.

Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review.

Kalaitzis IS, Rowbotham NJ, Smith SJ, Smyth AR.

J Cyst Fibros. 2019 Jun 21. pii: S1569-1993(19)30806-9. doi: 10.1016/j.jcf.2019.06.005. [Epub ahead of print]

PMID:
31235360
8.

Climate change and lung health: presidential failure, professional responsibility.

Hopkinson NS, Hart N, Jenkins G, Rosenfeld M, Smyth AR, Wilkinson AJK, Kaminski N.

Thorax. 2019 Jul;74(7):627-628. doi: 10.1136/thoraxjnl-2019-213184. Epub 2019 Apr 21. No abstract available.

9.

Patient engagement to prioritise CF research: Inclusive or selective?

Rowbotham NJ, Smyth AR.

J Cyst Fibros. 2019 May;18(3):307-308. doi: 10.1016/j.jcf.2019.04.006. Epub 2019 Apr 12. No abstract available.

PMID:
30982755
10.

Infection prevention and control in cystic fibrosis: a systematic review of interventions.

Rowbotham NJ, Palser SC, Smith SJ, Smyth AR.

Expert Rev Respir Med. 2019 May;13(5):425-434. doi: 10.1080/17476348.2019.1595594. Epub 2019 Mar 26.

PMID:
30892097
11.

Reply: More on Causal Inference Studies.

Lederer DJ, Bell SC, Smyth AR, Chalmers JD.

Ann Am Thorac Soc. 2019 May;16(5):646. doi: 10.1513/AnnalsATS.201901-070LE. No abstract available.

12.

Is microfinance associated with changes in women's well-being and children's nutrition? A systematic review and meta-analysis.

Gichuru W, Ojha S, Smith S, Smyth AR, Szatkowski L.

BMJ Open. 2019 Jan 28;9(1):e023658. doi: 10.1136/bmjopen-2018-023658.

13.

Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review.

Rowbotham NJ, Smith S, Prayle AP, Robinson KA, Smyth AR.

Thorax. 2019 Mar;74(3):229-236. doi: 10.1136/thoraxjnl-2017-210858. Epub 2018 Oct 9.

PMID:
30301819
14.

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.

Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, Stewart PW, Suissa S, Adjei AA, Akdis CA, Azoulay É, Bakker J, Ballas ZK, Bardin PG, Barreiro E, Bellomo R, Bernstein JA, Brusasco V, Buchman TG, Chokroverty S, Collop NA, Crapo JD, Fitzgerald DA, Hale L, Hart N, Herth FJ, Iwashyna TJ, Jenkins G, Kolb M, Marks GB, Mazzone P, Moorman JR, Murphy TM, Noah TL, Reynolds P, Riemann D, Russell RE, Sheikh A, Sotgiu G, Swenson ER, Szczesniak R, Szymusiak R, Teboul JL, Vincent JL.

Ann Am Thorac Soc. 2019 Jan;16(1):22-28. doi: 10.1513/AnnalsATS.201808-564PS. No abstract available. Erratum in: Ann Am Thorac Soc. 2019 Feb;16(2):283.

15.

Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Jain K, Wainwright C, Smyth AR.

Cochrane Database Syst Rev. 2018 Sep 17;9:CD009530. doi: 10.1002/14651858.CD009530.pub4. Review.

16.

Staphylococcus aureus in cystic fibrosis: pivotal role or bit part actor?

Hurley MN, Smyth AR.

Curr Opin Pulm Med. 2018 Nov;24(6):586-591. doi: 10.1097/MCP.0000000000000518. Review.

PMID:
30113336
17.

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Lo DK, Muhlebach MS, Smyth AR.

Cochrane Database Syst Rev. 2018 Jul 21;7:CD009650. doi: 10.1002/14651858.CD009650.pub4. Review.

18.

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P.

J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.

19.

Variation in benthic metabolism and nitrogen cycling across clam aquaculture sites.

Murphy AE, Nizzoli D, Bartoli M, Smyth AR, Castaldelli G, Anderson IC.

Mar Pollut Bull. 2018 Feb;127:524-535. doi: 10.1016/j.marpolbul.2017.12.003. Epub 2017 Dec 21.

PMID:
29475692
20.

Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study; response to comments.

Barr HL, Halliday N, Barrett DA, Williams P, Forrester DL, Peckham D, Williams K, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ, Cámara M, Fogarty AW.

J Cyst Fibros. 2017 Nov;16(6):e21. doi: 10.1016/j.jcf.2017.09.008. Epub 2017 Oct 25. No abstract available.

21.

Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis.

Hurley MN, Fogarty A, McKeever TM, Goss CH, Rosenfeld M, Smyth AR.

Ann Am Thorac Soc. 2018 Jan;15(1):42-48. doi: 10.1513/AnnalsATS.201705-376OC.

22.

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.

Rowbotham NJ, Smith S, Leighton PA, Rayner OC, Gathercole K, Elliott ZC, Nash EF, Daniels T, Duff AJA, Collins S, Chandran S, Peaple U, Hurley MN, Brownlee K, Smyth AR.

Thorax. 2018 Apr;73(4):388-390. doi: 10.1136/thoraxjnl-2017-210473. Epub 2017 Aug 4.

23.

Investigating the variation in the incidence of new Pseudomonas aeruginosa infection between paediatric cystic fibrosis centres.

Gilchrist FJ, Jones AM, Smyth AR, Southern KW, Webb AK, Lenney W.

J Cyst Fibros. 2017 Sep;16(5):e14-e16. doi: 10.1016/j.jcf.2017.06.006. Epub 2017 Jul 6. No abstract available.

24.

Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review.

Prayle AP, Cox T, Smith SJ, Rycroft-Malone J, Thomas KS, Hughes DA, Smyth AR.

Thorax. 2017 Apr 26. pii: thoraxjnl-2016-208790. doi: 10.1136/thoraxjnl-2016-208790. [Epub ahead of print]

25.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD004197. doi: 10.1002/14651858.CD004197.pub5. Review.

26.

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.

Smyth AR, Rosenfeld M.

Cochrane Database Syst Rev. 2017 Apr 18;4:CD001912. doi: 10.1002/14651858.CD001912.pub4. Review.

27.

Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.

Smyth AR, Bhatt J, Nevitt SJ.

Cochrane Database Syst Rev. 2017 Mar 27;3:CD002009. doi: 10.1002/14651858.CD002009.pub6. Review. Update in: Cochrane Database Syst Rev. 2019 Sep 04;9:CD002009.

28.

The patient voice in research - Supporting actor or starring role?

Rowbotham NJ, Smyth AR.

J Cyst Fibros. 2017 May;16(3):313-314. doi: 10.1016/j.jcf.2017.03.001. Epub 2017 Mar 9. No abstract available.

29.

Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study.

Palser SC, Rayner OC, Leighton PA, Smyth AR.

BMJ Open. 2016 Dec 28;6(12):e012303. doi: 10.1136/bmjopen-2016-012303.

30.

Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study.

Barr HL, Halliday N, Barrett DA, Williams P, Forrester DL, Peckham D, Williams K, Smyth AR, Honeybourne D, L Whitehouse J, Nash EF, Dewar J, Clayton A, Knox AJ, Cámara M, Fogarty AW.

J Cyst Fibros. 2017 Mar;16(2):230-238. doi: 10.1016/j.jcf.2016.10.005. Epub 2016 Oct 20.

31.

Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Gilchrist FJ, Belcher J, Jones AM, Smith D, Smyth AR, Southern KW, Španěl P, Webb AK, Lenney W.

ERJ Open Res. 2015 Nov 16;1(2). pii: 00044-2015. eCollection 2015 Oct.

32.

First year of the thoracic triumvirate.

Hart N, Jenkins G, Smyth AR.

Thorax. 2016 Jul;71(7):579-80. doi: 10.1136/thoraxjnl-2016-208959. No abstract available.

PMID:
27302630
33.

Thorax protocol review: working with trialists to improve trial quality.

Shyamsundar M, Smyth AR, McAuley DF.

Thorax. 2016 Jun;71(6):491-2. doi: 10.1136/thoraxjnl-2016-208331. Epub 2016 Apr 5. No abstract available.

PMID:
27048198
34.

Extending Rapid Ecosystem Function Assessments to Marine Ecosystems: A Reply to Meyer.

Lefcheck JS, Brandl SJ, Reynolds PL, Smyth AR, Meyer ST.

Trends Ecol Evol. 2016 Apr;31(4):251-253. doi: 10.1016/j.tree.2016.02.002. Epub 2016 Feb 25. No abstract available.

PMID:
26922421
35.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

36.

Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Jain K, Wainwright C, Smyth AR.

Cochrane Database Syst Rev. 2016 Jan 21;(1):CD009530. doi: 10.1002/14651858.CD009530.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Sep 17;9:CD009530.

PMID:
26797965
37.

Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.

Forrester DL, Knox AJ, Smyth AR, Barr HL, Simms R, Pacey SJ, Pavord ID, Honeybourne D, Dewar J, Clayton A, Fogarty AW.

Pediatr Pulmonol. 2016 Mar;51(3):253-7. doi: 10.1002/ppul.23370. Epub 2015 Dec 27.

PMID:
26709241
38.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS.

Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

39.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society.

Thorax. 2016 Jan;71 Suppl 1:i1-22. doi: 10.1136/thoraxjnl-2015-207360.

40.

Correction to Scientific Evidence Supports a Ban on Microbeads.

Rochman CM, Kross SM, Armstrong JB, Bogan MT, Darling ES, Green SJ, Smyth AR, Veríssimo D.

Environ Sci Technol. 2015 Dec 15;49(24):14740. doi: 10.1021/acs.est.5b05043. Epub 2015 Nov 13. No abstract available.

PMID:
26565431
41.

Scientific Evidence Supports a Ban on Microbeads.

Rochman CM, Kross SM, Armstrong JB, Bogan MT, Darling ES, Green SJ, Smyth AR, Veríssimo D.

Environ Sci Technol. 2015 Sep 15;49(18):10759-61. doi: 10.1021/acs.est.5b03909. Epub 2015 Sep 3. No abstract available. Erratum in: Environ Sci Technol. 2015 Dec 15;49(24):14740.

PMID:
26334581
42.

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.

Prayle AP, Jain K, Touw DJ, Koch BC, Knox AJ, Watson A, Smyth AR.

J Cyst Fibros. 2016 Jul;15(4):510-7. doi: 10.1016/j.jcf.2015.07.012. Epub 2015 Aug 15.

43.

Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis.

Barr HL, Halliday N, Cámara M, Barrett DA, Williams P, Forrester DL, Simms R, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ, Fogarty AW.

Eur Respir J. 2015 Oct;46(4):1046-54. doi: 10.1183/09031936.00225214. Epub 2015 May 28.

44.

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Lo DK, Hurley MN, Muhlebach MS, Smyth AR.

Cochrane Database Syst Rev. 2015 Feb 24;(2):CD009650. doi: 10.1002/14651858.CD009650.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Jul 21;7:CD009650.

PMID:
25927091
45.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

46.

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.

Smyth AR, Walters S.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD001912. doi: 10.1002/14651858.CD001912.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Apr 18;4:CD001912.

PMID:
25419599
47.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Review. Update in: Cochrane Database Syst Rev. 2017 Apr 25;4:CD004197.

PMID:
25383937
48.

Feasibility and pilot study of the effects of microfinance on mortality and nutrition in children under five amongst the very poor in India: study protocol for a cluster randomized controlled trial.

Ojha S, Szatkowski L, Sinha R, Yaron G, Fogarty A, Allen S, Choudhary S, Smyth AR.

Trials. 2014 Jul 23;15:298. doi: 10.1186/1745-6215-15-298.

49.

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.

Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S; European Cystic Fibrosis Society.

J Cyst Fibros. 2014 May;13 Suppl 1:S23-42. doi: 10.1016/j.jcf.2014.03.010. Review.

50.

Standards of Care for Cystic Fibrosis ten years later.

Castellani C, Conway S, Smyth AR, Stern M, Elborn JS.

J Cyst Fibros. 2014 May;13 Suppl 1:S1-2. doi: 10.1016/j.jcf.2014.03.008. No abstract available.

Supplemental Content

Loading ...
Support Center